A Phase 1 study of ONO-7057 in patients with relapsed and/or refractory multiple myeloma (ONO-7057-05)
Latest Information Update: 10 Jan 2022
At a glance
- Drugs Carfilzomib (Primary) ; Dexamethasone (Primary) ; Dexamethasone (Primary) ; Lenalidomide (Primary)
- Indications Multiple myeloma
- Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
- Sponsors Ono Pharmaceutical
- 12 Feb 2018 Status changed from active, no longer recruiting to completed.
- 06 Jun 2016 New trial record